CJC-1295 vs Mod GRF 1-29 vs Tesamorelin
A three-way comparison to help you find the right peptide for your research goals.
CJC-1295
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone.
Full details →Mod GRF 1-29
Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.
Full details →Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
Full details →Side-by-Side Comparison
| Aspect | CJC-1295 | Mod GRF 1-29 | Tesamorelin |
|---|---|---|---|
| Mechanism | CJC-1295 binds to GHRH receptors in the pituitary, triggering increased production and release of growth hormone. The DAC (Drug Affinity Complex) version extends half-life significantly. | Binds to GHRH receptors in the pituitary gland to stimulate growth hormone release. Four amino acid substitutions improve resistance to enzymatic degradation while maintaining biological activity. | Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue. |
| Typical Dosage | CJC-1295 DAC: 1-2mg weekly. CJC-1295 no DAC (Mod GRF 1-29): 100-300mcg 2-3 times daily. | Typical dosing: 100-300mcg administered 2-3 times daily, usually combined with a GHRP like Ipamorelin for synergistic effects. | FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules. |
| Administration | Subcutaneous injection, often combined with a GHRP like Ipamorelin for synergistic effects. Best administered before sleep or fasted. | Subcutaneous injection. Best administered on empty stomach. Short half-life (~30 minutes) necessitates multiple daily doses, unlike DAC version. | Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening. |
| Side Effects | Water retention, tingling in extremities, potential increase in cortisol and prolactin levels. | Flushing, headache, dizziness, and injection site reactions. Generally well-tolerated. May cause water retention. | Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose. |
| Best For |
What They Have in Common
CJC-1295, Mod GRF 1-29, Tesamorelin are all commonly used for:
Key Differences
Unique to CJC-1295:
Unique to Mod GRF 1-29:
Detailed Analysis
Commonalities
Both CJC-1295 and Mod GRF 1-29 are commonly used for Muscle Growth, Fat Loss, Sleep Quality.
Which Should You Choose?
CJC-1295 has stronger evidence for Fat Loss.
Commonalities
Both CJC-1295 and Tesamorelin are commonly used for Muscle Growth, Fat Loss.
Which Should You Choose?
CJC-1295 has stronger evidence for Muscle Growth.
Commonalities
Both Mod GRF 1-29 and Tesamorelin are commonly used for Muscle Growth, Fat Loss.
Which Should You Choose?
Mod GRF 1-29 has stronger evidence for Muscle Growth. Tesamorelin has stronger evidence for Fat Loss.